KITLG and Alzheimer disease: In the rats with AD induced by bilaterally infusing amyloid-β (25–35) into the hippocampus, the 0.5% SCF intake mitigated hippocampal amyloid-β deposition, neuroinflammation, memory deficits, and dysregulated glucose and lipid metabolism versus the AD controls.